Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ConCab: Weekly vs 3-weekly Cabazitaxel in mCRPC
NCT01541007Phase 2Completed
- Start
- Apr 2012
- Primary completion
- Oct 2015
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC). Started Apr 2012; status: completed.
02
Drugs
cabazitaxel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01541007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01541007.